Screening for diabetes in patients with cardiovascular disease: HbA1c trumps oral glucose tolerance testing
Optimum, cost-effective, and pragmatic screening for and diagnosis of important health disorders remains a key aspect of clinical care. With this in mind, the American Diabetes Association formally accepted the use of HbA1c as a diagnostic test for type 2 diabetes in January, 2010.1 Although this de...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
Lancet
2016
|
| Summary: | Optimum, cost-effective, and pragmatic screening for and diagnosis of important health disorders remains a key aspect of clinical care. With this in mind, the American Diabetes Association formally accepted the use of HbA1c as a diagnostic test for type 2 diabetes in January, 2010.1 Although this decision was opposed by some, key organisations accepted use of HbA1c as a diagnostic test. HbA1c was subsequently added to the diagnosis algorithm for type 2 diabetes in the joint European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) guidelines2 on the management of diabetes and cardiovascular disease. |
|---|